{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:08:48Z","timestamp":1790795328420,"version":"4.1.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.cllc.2022.10.008","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T10:10:13Z","timestamp":1668161413000},"page":"e65-e68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9068-8942","authenticated-orcid":false,"given":"John","family":"Heymach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans","family":"Opdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minal","family":"Barve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behbood","family":"Sadrolhefazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2022.10.008_bib0001","doi-asserted-by":"crossref","first-page":"e000279","DOI":"10.1136\/esmoopen-2017-000279","article-title":"Activating HER2 mutations as emerging targets in multiple solid cancers","volume":"2","author":"Connell","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.cllc.2022.10.008_bib0002","doi-asserted-by":"crossref","first-page":"e1303","DOI":"10.1634\/theoncologist.2018-0845","article-title":"Emergence of ERBB2 mutation as a biomarker and an actionable target in solid cancers","volume":"24","author":"Subramanian","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2022.10.008_bib0003","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ccell.2019.09.001","article-title":"Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity","volume":"36","author":"Robichaux","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cllc.2022.10.008_bib0004","doi-asserted-by":"crossref","first-page":"102906","DOI":"10.1016\/j.critrevonc.2020.102906","article-title":"Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC","volume":"148","author":"Baraibar","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.cllc.2022.10.008_bib0005","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41591-018-0007-9","article-title":"Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer","volume":"24","author":"Robichaux","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.cllc.2022.10.008_bib0006","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/ajco.12687","article-title":"Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities","volume":"14","author":"Aw","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"issue":"Suppl13","key":"10.1016\/j.cllc.2022.10.008_bib0007","doi-asserted-by":"crossref","first-page":"Abstr1472","DOI":"10.1158\/1538-7445.AM2021-1472","article-title":"Novel EGFR WT sparing, HER2 selective inhibitors for the treatment of HER2 exon 20 insertion driven tumors address a clear unmet medical need","volume":"81","author":"Neum\u00fcller","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2022.10.008_bib0008","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.10.008_bib0009","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1200\/JCO.21.01113","article-title":"Poziotinib for patients with HER2 exon 20 mutant non-small-cell lung cancer: results from a Phase II trial","volume":"40","author":"Elamin","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.10.008_bib0010","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.21.01323","article-title":"Poziotinib in non-small-cell lung cancer harboring HER2 exon 20 insertion mutations after prior therapies: ZENITH20-2 trial","volume":"40","author":"Le","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.10.008_bib0011","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12916-022-02245-z","article-title":"Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial","volume":"20","author":"Song","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.cllc.2022.10.008_bib0012","unstructured":"FDA. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for 233 HER2-mutant non-small cell lung cancer. Food and Drug Administration: Silver Spring, MD, USA; 2022. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung."}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422002571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422002571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:15:05Z","timestamp":1761506105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730422002571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1525730422002571"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2022.10.008","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2022.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}